<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   AIDS-related Kaposi sarcoma: Staging and treatment
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       AIDS-related Kaposi sarcoma: Staging and treatment
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        AIDS-related Kaposi sarcoma: Staging and treatment
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jerome E Groopman, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David M Aboulafia, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Melinda Yushak, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 05, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Kaposi sarcoma (KS) is a low-grade vascular tumor associated with infection with human herpesvirus 8 (HHV-8), also known as the KS-associated herpesvirus (KSHV).
        </p>
        <p>
         AIDS-related KS has a variable clinical course, ranging from minimal disease presenting as an incidental finding to a rapidly progressing neoplasm that can result in significant morbidity and mortality, depending upon the specific sites of involvement [
         <a href="#rid1">
          1
         </a>
         ]. In addition to physical symptoms due to tumors, the psychosocial burden associated with KS may be profound and includes emotional distress, guilt, and anger [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         The staging and treatment of AIDS-related Kaposi sarcoma are discussed here. The clinical manifestations and diagnosis of this disorder are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8033.html" rel="external">
          "AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H432035701">
         <span class="h1">
          STAGING AND EVALUATION
         </span>
        </p>
        <p class="headingAnchor" id="H432035415">
         <span class="h2">
          Staging system
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most commonly utilized staging system for AIDS-related KS was developed by the AIDS Clinical Trial Group (ACTG) of the National Institute of Health [
         <a href="#rid3">
          3
         </a>
         ]. This system divides patients into good or poor risk prognostic categories, taking into account both the KS and HIV infection.
        </p>
        <p>
         Patients are categorized according to three parameters (
         <a class="graphic graphic_table graphicRef54626" href="/z/d/graphic/54626.html" rel="external">
          table 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Extent of tumor (T)
         </strong>
         – A favorable prognosis (T0) is associated with disease limited to the skin or with minimal involvement of the oral cavity. Those with associated lymphedema, more extensive oral cavity involvement, or other visceral disease are considered to have a poor prognosis (T1).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immune status (I)
         </strong>
         – The degree of immunosuppression from the HIV infection is an important prognostic factor. Patients with a CD4 count greater than 200 cells/microL are considered to have a favorable prognosis (I0) while those with a lower CD4 count have classified as poor prognosis (I1).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Severity of systemic illness (S)
         </strong>
         – Features associated with a poor risk included the following (S1): a history of opportunistic infection, thrush, B symptoms (fever, night sweats, significant weight loss, diarrhea for more than two weeks). Patients without any of these factors have a more favorable prognosis (S0).
        </p>
        <p>
        </p>
        <p>
         The overall patient assessment requires that good-risk patients have a favorable prognosis according to all three parameters. This was illustrated by an analysis of 144 patients with KS prospectively included in the Swiss HIV Cohort Study [
         <a href="#rid4">
          4
         </a>
         ]. On multivariate analysis, factors significantly associated with death or a need for chemotherapy included tumor stage T1 rather than T0, a CD4 count &lt;200 cells/microL, or a positive test for human herpesvirus 8 (HHV-8) DNA (hazard ratios 5.2, 2.3, and 2.1, respectively).
        </p>
        <p>
         Although there is no American Joint Committee on Cancer (AJCC) staging system for KS, the AJCC recommends recording the size of the largest lesion, if possible, although this may not be feasible given confluency of lesions [
         <a href="#rid5">
          5
         </a>
         ]. Although the AJCC also notes that previous systems involving the immune status of the patient may be less relevant, given the availability of antiretroviral therapy, it is our view that the immune status of the patient is important. For example, treatment to restore immune integrity with robust CD4+ numbers can in itself result in both regression of some lesions and better response to anti-KS modalities.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Initial evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial evaluation of a patient with KS consists of a thorough physical examination with special attention paid to those areas typically affected by the disease, such as the lower extremities, face, oral mucosa, genitalia, gastrointestinal tract, and lungs. (See
         <a class="medical medical_review" href="/z/d/html/8033.html" rel="external">
          "AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
         Evaluation for visceral involvement is guided by symptomatology and basic laboratory testing.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Testing the stool for occult blood is the simplest way to screen for gastrointestinal involvement. Endoscopy is usually reserved for patients who test positive for occult blood or have gastrointestinal symptoms.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chest x-ray is useful to screen for pulmonary lesions. Bronchoscopy should be reserved for those with an abnormal radiograph and persistent respiratory symptoms in the absence of another cause.
        </p>
        <p>
        </p>
        <p>
         CT scanning of the chest, abdomen, and pelvis is typically not necessary.
        </p>
        <p>
         The CD4 cell count and HIV viral load are important for staging and prognosis, and thus may be useful in making treatment decisions. (See
         <a class="medical medical_review" href="/z/d/html/3740.html" rel="external">
          "Techniques and interpretation of measurement of the CD4 cell count in people with HIV"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3743.html" rel="external">
          "Techniques and interpretation of HIV-1 RNA quantitation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The major goals of treatment are symptom palliation, prevention of disease progression, and shrinkage of tumor to alleviate edema, organ compromise, and psychological stress [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         Systemic treatment with potent combination antiretroviral therapy (ART) is recommended for virtually all patients with AIDS-related KS [
         <a href="#rid6">
          6-9
         </a>
         ]. The need for treatment beyond ART and the choice among the various options depend upon the extent of disease, the rapidity of tumor growth, the HIV-1 viral load, the CD4 cell count, and the patient's overall medical condition [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         Locally directed therapy is often used to palliate symptoms caused by a specific tumor or to treat cosmetic disfigurement. Systemic therapy is used for more extensive disease but injury to an immune system that is already severely compromised should be avoided whenever possible.
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Combined antiretroviral therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Combination ART is recommended for virtually all patients with AIDS-related KS, and may be the only therapy required in the absence of specific indications for chemotherapy. For those in whom chemotherapy is indicated, it may be combined effectively and safely with ART. (See
         <a class="local">
          'Systemic therapy'
         </a>
         below.)
        </p>
        <p>
         The introduction of ART has been associated with a substantial decrease in both the incidence and severity of newly diagnosed KS in HIV infected patients. A French database study that included 54,999 patients with over 180,000 patient years of follow-up found that the incidence rate for new cases of KS fell from 32 per 1000 person-years in 1993-1994 to 3 per 1000 person-years after 1999 [
         <a href="#rid11">
          11
         </a>
         ]. Furthermore, the incidence of visceral involvement at presentation fell from more than 50 percent to less than 30 percent. Similar dramatic decreases have been seen in other studies [
         <a href="#rid12">
          12,13
         </a>
         ].
        </p>
        <p>
         Observational studies indicate that the natural history of AIDS-related KS has changed since the introduction of ART in addition to a decrease in the KS incidence [
         <a href="#rid14">
          14,15
         </a>
         ]. A retrospective study that analyzed KS cases from a database of 4439 persons with HIV infection both before ART (1990 to 1996) and after ART (1997 to 2002) found that the mean CD4 count and the mean HIV RNA levels were similar in the 366 patients from the pre-ART era and in the 40 patients in the post-ART era [
         <a href="#rid15">
          15
         </a>
         ]. However, the overall risk of dying was significantly lower in the post-ART era (hazard ratio, 0.24).
        </p>
        <p>
         Immune reconstitution due to control of the HIV infection is the most likely explanation for this altered prognosis rather than a direct effect on tumor. Although HIV protease inhibitors have antiangiogenic properties and block the development and progression of KS-like lesions in nude mice [
         <a href="#rid16">
          16
         </a>
         ], there was no difference in the likelihood of clinical response associated with the use of these agents [
         <a href="#rid14">
          14,17
         </a>
         ]. Furthermore, the decreased incidence of KS has been observed with ART regimens that do not contain protease inhibitors [
         <a href="#rid11">
          11
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">
          "Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"
         </a>
         .)
        </p>
        <p>
         Although treatment with ART causes increases in CD4 counts above the levels typically associated with increased susceptibility to infection, some patients develop HIV-related KS despite apparent correction of their immunodeficiency [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h3">
          Immune reconstitution inflammatory syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         The term "immune reconstitution inflammatory syndrome" (IRIS) describes a collection of host responses that can occur following the initiation of ART. In addition to worsening of symptoms from preexisting infections with IRIS, the initiation of ART has been associated with progression of KS within three to six weeks after starting antiretroviral therapy [
         <a href="#rid19">
          19,20
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3762.html" rel="external">
          "Immune reconstitution inflammatory syndrome"
         </a>
         .)
        </p>
        <p>
         The relationship between IRIS and KS is illustrated by a series of 150 therapy-naive patients who presented with KS, 10 (7 percent) developed progressive KS when ART was initiated [
         <a href="#rid19">
          19
         </a>
         ]. The risk of IRIS appeared to be increased in those with a higher CD4 count or KS-associated edema. Despite the progression of KS, continuation of ART was possible in these patients. Other large series have made similar observations [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
         Factors associated with an increased risk of IRIS in patients initiating ART for HIV include more extensive (T1) KS, a higher HIV viral load, and the use of ART without chemotherapy [
         <a href="#rid21">
          21
         </a>
         ]. Progression of KS in patients with IRIS can be severe and has been associated with death in some cases [
         <a href="#rid21">
          21-23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Local symptomatic therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Local treatment modalities are useful for cosmesis or the management of limited, symptomatic bulky KS lesions, but they do not prevent the development of new lesions in untreated areas.
        </p>
        <p>
         The most widely used local treatment approaches include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intralesional chemotherapy
         </strong>
         – Intralesional chemotherapy can induce regression of injected tumors and is preferred for small lesions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="10044" href="/z/d/drug information/10044.html" rel="external">
          Vinblastine
         </a>
         is the most widely used agent. It can be injected directly into a KS lesion as a 0.2 to 0.3 mg/mL solution with a volume of 0.1 mL per 0.5 cm
         <sup>
          2
         </sup>
         of lesion. Multiple injections may be necessary for larger lesions. A second series of injections is often necessary three to four weeks later. Treated lesions will fade and regress although typically not resolve completely [
         <a href="#rid24">
          24-26
         </a>
         ]. In one series of 42 patients with oral KS, for example, 74 percent showed more than a 50 percent reduction in lesions; palliation was achieved for a mean of 4.3 months [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Radiation therapy
         </strong>
         – The primary role of radiation therapy is to treat symptomatic disease that is too extensive to be treated with intralesional chemotherapy [
         <a href="#rid27">
          27
         </a>
         ], but is not extensive enough to require systemic therapy. Although discomfort from radiotherapy is frequent, it usually resolves within two weeks of treatment. Radiation therapy does not have a role in patients with extensive KS, as was illustrated by a randomized trial from Zimbabwe [
         <a href="#rid28">
          28
         </a>
         ]. In this trial, radiation therapy did not improve either quality of life or survival compared to supportive care alone in 495 patients who were not treated with antiretroviral drugs.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Topical
         </strong>
         <a class="drug drug_general" data-topicid="9366" href="/z/d/drug information/9366.html" rel="external">
          alitretinoin
         </a>
         <strong>
         </strong>
         – Alitretinoin (9-cis retinoic acid) is available as a topical gel that the patient can apply to treat cutaneous KS lesions. This agent is rarely used, since the topical gel can cause inflammation and lead to pigmentation changes in dark-skinned patients. In two phase III studies involving 402 patients, alitretinoin was associated with a shorter time to response, a longer duration of response, and a longer time to disease progression compared to a placebo vehicle gel [
         <a href="#rid29">
          29,30
         </a>
         ]. In these trials, responses were seen in 35 and 37 percent of patients after 12 weeks of treatment, compared to 7 and 18 percent with placebo. Responses were seen in patients with a wide range of baseline CD4+ lymphocyte counts.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h2">
          Systemic therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who have advanced or rapidly progressive KS, we suggest initial therapy with both systemic chemotherapy and ART [
         <a href="#rid7">
          7,9
         </a>
         ]. When chemotherapy is indicated, we prefer initial treatment with
         <a class="drug drug_general" data-topicid="10135" href="/z/d/drug information/10135.html" rel="external">
          pegylated liposomal doxorubicin
         </a>
         [
         <a href="#rid7">
          7
         </a>
         ]. Other options include
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         ,
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10044" href="/z/d/drug information/10044.html" rel="external">
          vinblastine
         </a>
         ,
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         , and
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         [
         <a href="#rid31">
          31
         </a>
         ]. (See
         <a class="local">
          'Liposomal doxorubicin (preferred)'
         </a>
         below and
         <a class="local">
          'Paclitaxel'
         </a>
         below.)
        </p>
        <p>
         Generally accepted indications for adding systemic chemotherapy to ART include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Widespread skin involvement (eg, more than 25 lesions)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Extensive cutaneous KS that is unresponsive to local treatment
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Extensive edema
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Symptomatic visceral involvement
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immune reconstitution inflammatory syndrome (IRIS) (see
         <a class="local">
          'Immune reconstitution inflammatory syndrome'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Progression of KS on ART alone
        </p>
        <p>
        </p>
        <p>
         Small randomized trials have looked at the role of chemotherapy plus ART versus ART alone, and while typically response rates are higher with the addition of chemotherapy to ART, a survival benefit has not been demonstrated. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one trial, 112 patients who had not received prior ART or chemotherapy for KS were randomly assigned to ART (
         <a class="drug drug_general" data-topicid="9946" href="/z/d/drug information/9946.html" rel="external">
          stavudine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">
          lamivudine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9694" href="/z/d/drug information/9694.html" rel="external">
          nevirapine
         </a>
         ) with or without combination chemotherapy (
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         , and
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         ) [
         <a href="#rid32">
          32
         </a>
         ]. The trial was limited to patients without symptomatic visceral disease or fungating lesions requiring urgent therapy. The overall response rate of the KS was significantly better for patients given chemotherapy plus ART (66 versus 39 percent). However, overall survival was 77 percent for the entire study population and there was no significant difference between the study arms.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One trial randomly assigned 190 HIV-infected adults with mild to moderate KS initiating ART to immediate
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         or etoposide upon KS progression [
         <a href="#rid33">
          33
         </a>
         ]. Although immediate etoposide delayed KS progression and decreased time to initial KS response, mortality was similar between the two groups at 48 weeks.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Finally, in a smaller trial, 28 patients with moderate or advanced KS who were initiating a new ART regimen were randomly assigned to ART plus liposomal
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         or ART alone [
         <a href="#rid34">
          34
         </a>
         ]. Among those receiving chemotherapy with ART, 10 of 13 (76 percent) responded, compared with 3 of 15 (20 percent) with ART alone. Survival results were not reported.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4232397247">
         <span class="h3">
          Initial therapy
         </span>
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h4">
          Liposomal doxorubicin (preferred)
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with AIDS-related KS who have an indication for systemic therapy, we suggest initial therapy with
         <a class="drug drug_general" data-topicid="10135" href="/z/d/drug information/10135.html" rel="external">
          pegylated liposomal doxorubicin
         </a>
         rather than a combination of older agents or a taxane [
         <a href="#rid7">
          7
         </a>
         ]. Liposomal
         <a class="drug drug_general" data-topicid="9326" href="/z/d/drug information/9326.html" rel="external">
          daunorubicin
         </a>
         was previously recommended for use as an option for first-line therapy [
         <a href="#rid7">
          7
         </a>
         ]. However, liposomal daunorubicin is no longer available.
        </p>
        <p>
         Pegylated
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         has a longer plasma half-life than a nonliposomal formulation. A liposomal formulation has less toxicity in nontarget organs than a conventional anthracycline and provides the theoretical advantage of higher tumor concentrations of drug. (See
         <a class="medical medical_review" href="/z/d/html/107443.html" rel="external">
          "Risk and prevention of anthracycline cardiotoxicity", section on 'Modification of dose, specific agent, and schedule of administration'
         </a>
         .)
        </p>
        <p>
         Liposomal
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         can reliably shrink tumors, lessen edema, and cause the color of lesions to fade. Response rates range from 30 to 60 percent depending upon the definition of clinical response and the specifics of the various trials. In randomized multicenter trials, it was as effective as or superior to conventional combination chemotherapy (
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         and
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         with or without nonliposomal doxorubicin) in terms of response rates and had a better toxicity profile [
         <a href="#rid35">
          35,36
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one trial, 258 patients were randomly assigned to
         <a class="drug drug_general" data-topicid="10135" href="/z/d/drug information/10135.html" rel="external">
          pegylated liposomal doxorubicin
         </a>
         (20 mg/m
         <sup>
          2
         </sup>
         every three weeks) or a combination regimen of
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         , and
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         [
         <a href="#rid35">
          35
         </a>
         ]. The response rate (virtually all responses were partial) was significantly higher with pegylated liposomal doxorubicin (46 versus 25 percent), which was also associated with less toxicity. Similar findings were noted in another trial of 241 patients (59 versus 23 percent response rate) [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a randomized trial of 73 patients with HIV-associated KS, those randomly assigned to liposomal
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         experienced comparable response rates, median progression-free survival, and two-year survival rates as those assigned to
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         [
         <a href="#rid37">
          37
         </a>
         ]. There was, however, a nonsignificant trend towards less frequent grade 3 to 5 toxicity for liposomal doxorubicin (66 versus 84 percent, respectively), making it the preferable option.
        </p>
        <p>
        </p>
        <p>
         Side effects from liposomal
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         are generally mild. In particular, alopecia and neuropathies are unusual in contrast with the side effect profile of conventional combination chemotherapy regimens. The diminished cardiotoxicity with liposomal doxorubicin permits higher cumulative doses of anthracycline to be administered, lengthening the duration over which these agents may be used [
         <a href="#rid38">
          38,39
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/90854.html" rel="external">
          "Clinical manifestations, diagnosis, and treatment of anthracycline-induced cardiotoxicity"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/107443.html" rel="external">
          "Risk and prevention of anthracycline cardiotoxicity"
         </a>
         .)
        </p>
        <p>
         The potential for prolonged control of KS was illustrated by a study of 98 patients treated with ART plus
         <a class="drug drug_general" data-topicid="10135" href="/z/d/drug information/10135.html" rel="external">
          pegylated liposomal doxorubicin
         </a>
         between 1997 and 2002 [
         <a href="#rid40">
          40
         </a>
         ]. At a median follow-up of 29 months, 29 patients (30 percent) had died, including three with progressive KS. Among the 61 patients who had a complete or partial response of their KS, only eight (13 percent) relapsed after completing chemotherapy. The optimal duration of therapy with liposomal anthracycline is uncertain. A course of four to six cycles of liposomal
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         followed by a period of observation may be reasonable.
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h4">
          Paclitaxel
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         is potentially more toxic than the liposomal anthracyclines, it has striking efficacy as a subsequent treatment for KS [
         <a href="#rid41">
          41-45
         </a>
         ], and may be an alternative for initial therapy of patients with advanced, symptomatic KS, including those in resource-limited settings without access to liposomal anthracyclines [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
         In a randomized trial,
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         demonstrated similar response rates and survival when compared with
         <a class="drug drug_general" data-topicid="10135" href="/z/d/drug information/10135.html" rel="external">
          pegylated liposomal doxorubicin
         </a>
         and improved tumor-related symptoms, although the trial was terminated prematurely due to poor accrual. In this study, 73 patients were randomly assigned to paclitaxel (100 mg/m
         <sup>
          2
         </sup>
         every two weeks) or pegylated liposomal doxorubicin (20 mg/m
         <sup>
          2
         </sup>
         every three weeks) after the introduction of routine treatment with ART [
         <a href="#rid37">
          37
         </a>
         ]. At a median follow-up of 36 months, response rates for paclitaxel and pegylated
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         were 56 and 46 percent; median progression-free survival was 18 and 12 months; and two-year overall survival was 79 and 78 percent, respectively; these differences were not statistically significant. However, both paclitaxel and liposomal doxorubicin were associated with meaningful improvements in pain and swelling secondary to the tumor.
        </p>
        <p>
         In resource-limited settings where liposomal anthracycline may not be accessible,
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         plus ART is the preferred initial systemic agent, given better outcomes over other regimens such as oral
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         and
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         plus
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         [
         <a href="#rid46">
          46
         </a>
         ]. In an open-label, non-inferiority randomized trial, 334 patients with treatment-naïve AIDS-related Kaposi sarcoma in Africa and South America were randomly assigned to one of three treatment arms: oral etoposide, intravenous bleomycin plus vincristine, or standard of care intravenous paclitaxel (100 mg/m
         <sup>
          2
         </sup>
         every three weeks) [
         <a href="#rid46">
          46
         </a>
         ]. All patients received ART (combined
         <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">
          efavirenz
         </a>
         ,
         <a class="drug drug_general" data-topicid="9895" href="/z/d/drug information/9895.html" rel="external">
          tenofovir disoproxil fumarate
         </a>
         , and
         <a class="drug drug_general" data-topicid="8594" href="/z/d/drug information/8594.html" rel="external">
          emtricitabine
         </a>
         ) concurrently with chemotherapy. Both the etoposide and bleomycin plus vincristine arms were closed early due to inferiority to paclitaxel. At a median follow-up of approximately 62 weeks, paclitaxel improved 48-week progression-free survival rates relative to oral etoposide (50 versus 20 percent, respectively) and bleomycin plus vincristine (64 versus 44 percent, respectively). Objective response rates were better with paclitaxel versus oral etoposide (58 versus 31 percent, respectively), and comparable between paclitaxel and bleomycin plus vincristine (66 versus 61 percent). However, time to death was similar in all of the groups (48-week death rate of approximately 10 to 11 percent for paclitaxel; 26 percent for oral etoposide; and 19 percent for bleomycin plus vincristine).
        </p>
        <p>
         Similar outcomes were noted across all treatment arms for HIV-1 plasma RNA level suppression, improvement in CD4 counts, grade ≥3 toxicities, and both AIDS-defining and serious non-AIDS defining events.
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          Paclitaxel
         </a>
         plus ART also demonstrated a favorable safety profile; compared with paclitaxel, higher pain scores from peripheral neuropathy were seen for both
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         plus
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         (17 versus 7 percent) and oral
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         (7 versus 0 percent).
        </p>
        <p>
         The use of
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         regimens in KS patients is subject to two important interactions:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          Paclitaxel
         </a>
         administration requires premedication with glucocorticoids. Because of the concern that steroids may further immunosuppress HIV-infected patients and exacerbate KS, the
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         dose is typically reduced to 10 mg orally 12 and 6 hours prior to chemotherapy, instead of the usual 20 mg dose. (See
         <a class="medical medical_review" href="/z/d/html/2835.html" rel="external">
          "Infusion reactions to systemic chemotherapy", section on 'Taxanes'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          Paclitaxel
         </a>
         is metabolized through the cytochrome P450 enzymes, as are many of the antiretroviral drugs. Profound paclitaxel-related toxicity has been ascribed to an interaction between this drug and antiretroviral drugs in at least two patients [
         <a href="#rid47">
          47
         </a>
         ]. However, others have failed to document alterations in paclitaxel elimination pharmacokinetics in one patient treated concurrently with agents such as
         <a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">
          ritonavir
         </a>
         ,
         <a class="drug drug_general" data-topicid="9877" href="/z/d/drug information/9877.html" rel="external">
          saquinavir
         </a>
         , and
         <a class="drug drug_general" data-topicid="9694" href="/z/d/drug information/9694.html" rel="external">
          nevirapine
         </a>
         [
         <a href="#rid48">
          48
         </a>
         ]. Caution is urged when coadministering these agents. (See
         <a class="medical medical_review" href="/z/d/html/16352.html" rel="external">
          "Systemic therapy for malignancy in patients on antiretroviral medications"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H432040144">
         <span class="h4">
          Steroid reduction or withdrawal
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients being treated with steroids, KS lesions may regress upon reduction or withdrawal of steroids [
         <a href="#rid49">
          49,50
         </a>
         ].
        </p>
        <p>
         Corticosteroid therapy has been associated with the induction of KS and with the exacerbation of preexisting KS in HIV-infected persons, as well as in non-AIDS patients receiving corticosteroids for organ transplantation, autoimmune disorders, or lymphoproliferative diseases [
         <a href="#rid49">
          49
         </a>
         ]. The association of corticosteroids with KS is important because of the frequent use of these agents in HIV-infected patients with a variety of disorders including immune thrombocytopenia (ITP) and
         <em>
          Pneumocystis jirovecii
         </em>
         pneumonia.
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h3">
          Subsequent therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of other agents have been studied in a more limited way in patients with AIDS-related KS, and these may have utility as subsequent-line therapy. The choice amongst them is dependent upon the pace of disease progression and symptoms.
        </p>
        <p class="headingAnchor" id="H3658628321">
         <span class="h4">
          Rapidly progressive disease
         </span>
        </p>
        <p class="headingAnchor" id="H267520047">
         <span class="h5">
          Paclitaxel
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          Paclitaxel
         </a>
         is our preferred therapy for patients who have rapid progression after initial treatment with a liposomal anthracycline. The use of paclitaxel as subsequent therapy after liposomal
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         is discussed above. (See
         <a class="local">
          'Paclitaxel'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1257408632">
         <span class="h5">
          Vinorelbine
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10046" href="/z/d/drug information/10046.html" rel="external">
          Vinorelbine
         </a>
         may be effective in the treatment of patients with AIDS-related KS who have failed other treatments, including other vinca alkaloids. In one series of 35 patients treated with vinorelbine (30 mg/m
         <sup>
          2
         </sup>
         every two weeks), three (9 percent) had a complete clinical response, and 12 (34 percent) had a partial response, which lasted for a median of 151 days [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3219685644">
         <span class="h5">
          Etoposide
         </span>
         <span class="headingEndMark">
          —
         </span>
         Oral
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         has been reported to have activity in AIDS-related KS when given either in fractionated doses (20 mg/m
         <sup>
          2
         </sup>
         every eight hours for 7 of 21 days) [
         <a href="#rid52">
          52
         </a>
         ] or as a once daily dose of 50 mg for 7 of every 14 days [
         <a href="#rid53">
          53
         </a>
         ]. However, oral etoposide was inferior to
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         in a randomized trial. (See
         <a class="local">
          'Paclitaxel'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H377589550">
         <span class="h5">
          Gemcitabine
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          Gemcitabine
         </a>
         is a treatment option for patients with chemotherapy-naïve AIDS-related KS who have progressed despite combined ART, particularly in resource-limited settings. In a randomized phase II trial of 70 such patients in Western Kenya, gemcitabine demonstrated similar overall survival and response rates when compared with
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         plus
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         [
         <a href="#rid54">
          54,55
         </a>
         ]. Toxicity rates and improvements in health-related quality of life were also similar between the two groups [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3201652649">
         <span class="h4">
          Indolent disease (pomalidomide)
         </span>
         <span class="headingEndMark">
          —
         </span>
         For those with indolent, minimally symptomatic disease progression on chemotherapy and combined ART, we offer
         <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">
          pomalidomide
         </a>
         as an alternative to chemotherapy due to the potential for high response rates, favorable toxicity profile (eg, to avoid the alopecia and peripheral neuropathy associated with taxanes), and convenience of oral administration. However, chemotherapy (with
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         or other agents not previously received) is also a reasonable option in this setting, as pomalidomide has not been directly compared with chemotherapy in randomized trials. (See
         <a class="local">
          'Subsequent therapy'
         </a>
         above.)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">
          Pomalidomide
         </a>
         is an oral treatment option for patients with AIDS-related KS who have failed combined ART and have progressed on initial chemotherapy with liposomal anthracyclines. Combined ART should be continued concurrently with pomalidomide. ART management is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/13979.html" rel="external">
          "Selecting an antiretroviral regimen for treatment-experienced patients with HIV who are failing therapy"
         </a>
         .)
        </p>
        <p>
         Patients with AIDS-related KS may experience disease-related cytopenias and peripheral edema. Since
         <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">
          pomalidomide
         </a>
         can result in myelosuppression and venous thromboembolism (VTE), patients should have close monitoring of complete blood counts and receive appropriate VTE prophylaxis while on therapy. The approach to administration, VTE prophylaxis, and modification of pomalidomide dosing for organ dysfunction are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7729.html" rel="external">
          "Classic Kaposi sarcoma: Clinical features, staging, diagnosis, and treatment", section on 'Pomalidomide'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">
          Pomalidomide
         </a>
         was investigated in an open-label, single-arm phase I/II trial (12-C-0047) of 28 patients with KS, a majority of whom (75 percent) had previously received chemotherapy [
         <a href="#rid56">
          56
         </a>
         ]. Among the cohort of 18 HIV-positive patients, overall responses were seen in 12 patients (67 percent), including three complete responses (17 percent); median duration of response was 12.5 months. Grade ≥3 toxicities included neutropenia (50 percent), decreased phosphate (25 percent), elevated glucose (7 percent), elevated creatinine, rash, diarrhea, and peripheral edema (4 percent each). Neurologic toxicities related to pomalidomide are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2836.html" rel="external">
          "Overview of neurologic complications of conventional non-platinum cancer chemotherapy", section on 'Pomalidomide'
         </a>
         .)
        </p>
        <p>
         Based on these results, the US Food and Drug Administration (FDA) granted approval for
         <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">
          pomalidomide
         </a>
         in patients with AIDS-related KS after failure of combined ART [
         <a href="#rid57">
          57
         </a>
         ]. Pomalidomide has not been evaluated as initial therapy or directly compared with other available systemic therapies. Further studies are also needed to evaluate the long-term efficacy of this agent.
        </p>
        <p class="headingAnchor" id="H1606385272">
         <span class="h2">
          Is there a role for interferon alfa-2b?
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8563" href="/z/d/drug information/8563.html" rel="external">
          Interferon alfa-2b
         </a>
         produces clinically significant responses in approximately 20 to 40 percent of patients with AIDS-related KS, especially those with disease limited to the skin and relatively modest immunosuppression [
         <a href="#rid58">
          58,59
         </a>
         ]. Interferon alfa-2b is approved by the FDA for the treatment of patients with AIDS-related KS, but it is very rarely used because it has limited availability (as the manufacturer has discontinued production) and other agents have more favorable efficacy and toxicity profiles.
        </p>
        <p>
         In a randomized trial, patients with AIDS-related KS were treated with
         <a class="drug drug_general" data-topicid="10053" href="/z/d/drug information/10053.html" rel="external">
          zidovudine
         </a>
         and
         <a class="drug drug_general" data-topicid="8563" href="/z/d/drug information/8563.html" rel="external">
          interferon alfa-2b
         </a>
         at a dose of either one or eight million units subcutaneously per day [
         <a href="#rid59">
          59
         </a>
         ]. With the high-dose regimen, the response rate was much higher (31 versus 8 percent) and the median time to progression longer (18 versus 13 weeks). Responses at both doses were more likely in patients with CD4 counts above 150/microL. However, almost all patients in the high-dose arm required dose reduction for significant toxicity consisting of fever, chills, rigors, neutropenia, hepatotoxicity, and cognitive impairment.
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h1">
          EXPERIMENTAL APPROACHES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Advances in the understanding of the pathogenesis of KS are uncovering potential targets for KS therapies [
         <a href="#rid60">
          60,61
         </a>
         ]. Such targets include angiogenesis, sex hormones, vitamin D and its analogs, and cellular differentiation. Additional studies will be required to determine the role of these experimental therapies in KS patients. (See
         <a class="medical medical_review" href="/z/d/html/8033.html" rel="external">
          "AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1765576423">
         <span class="h2">
          Anti-HHV-8 therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Identification of human herpesvirus 8 (HHV-8) as the etiologic agent of KS provides another potential target for treatment. However, there are no specific anti-HHV-8 therapies available.
        </p>
        <p>
         Case-control studies of historical cohorts of HIV-seropositive subjects suggest that there is a lower incidence of KS in patients treated with
         <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">
          ganciclovir
         </a>
         or
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          foscarnet
         </a>
         , but not
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         [
         <a href="#rid62">
          62,63
         </a>
         ]. Indirect evidence for the efficacy of ganciclovir also comes from a randomized trial in which 377 HIV-seropositive patients with cytomegalovirus retinitis were assigned to receive a ganciclovir intraocular implant plus oral ganciclovir, a ganciclovir implant plus oral placebo, or intravenous ganciclovir alone [
         <a href="#rid64">
          64
         </a>
         ]. Treatment with oral or intravenous ganciclovir reduced the risk of KS by 75 and 93 percent, respectively, compared with placebo.
        </p>
        <p>
         New agents might inhibit the specific protein products of the virus that contribute to KS spindle cell growth as well as block the effects of the switched-on chemokine receptor. As this work progresses, the primary focus will be to sustain a high level of cellular immunity with antiretroviral therapy so that host defenses can provide the needed surveillance to suppress the neoplasm.
        </p>
        <p class="headingAnchor" id="H3326156892">
         <span class="h2">
          Other agents
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          Imatinib
         </a>
         <strong>
         </strong>
         – Activation of the platelet-derived growth factor (PDGF) and c-kit receptors (both receptor tyrosine kinases) are important in the growth of KS lesions and imatinib inhibits both of these receptors. In a multicenter phase II study, 30 patients were treated with imatinib for up to 12 months [
         <a href="#rid65">
          65
         </a>
         ]. Patients with symptomatic visceral disease requiring chemotherapy were excluded. Antiretroviral therapy was permitted but not required. Partial responses were observed in 10 patients (33 percent). Treatment was generally well tolerated and nine patients completed the full year of treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Inhibitors of mTOR pathway
         </strong>
         – Rapamycin and
         <a class="drug drug_general" data-topicid="10344" href="/z/d/drug information/10344.html" rel="external">
          temsirolimus
         </a>
         are inhibitors of the mechanistic target of rapamycin (mTOR) pathway and appear to have activity in patients with KS. The demonstration of patients who had regression of their transplant-related KS when treated with rapamycin indicates that the phosphoinositide 3-kinase/protein kinase B/mTOR (PI3K/AKT/mTOR) pathway may be important in the pathogenesis of KS [
         <a href="#rid66">
          66
         </a>
         ]. In another study, seven patients with HIV-related KS were treated with a combination of rapamycin plus antiretroviral therapy [
         <a href="#rid67">
          67
         </a>
         ]. Three patients, all on protease inhibitor containing regimens, had a partial response of their KS to treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          Bevacizumab
         </a>
         <strong>
         </strong>
         – Bevacizumab is a monoclonal antibody directed against vascular endothelial growth factor, which contributes to the pathogenesis of KS. In a phase II study, treatment of 17 patients with HIV associated KS using bevacizumab resulted in objective responses (complete or partial) in five cases and stable disease in nine additional cases [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Miscellaneous agents
         </strong>
         – A number of other agents have shown at least some evidence of activity in early studies in patients with AIDS-related KS. These include the angiogenesis inhibitors fumagillin [
         <a href="#rid69">
          69
         </a>
         ] and
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         [
         <a href="#rid70">
          70
         </a>
         ], the differentiation-inducing agent 9-cis retinoic acid [
         <a href="#rid71">
          71
         </a>
         ], the matrix metalloproteinase inhibitor COL-3 [
         <a href="#rid72">
          72
         </a>
         ], interleukin-12 [
         <a href="#rid73">
          73,74
         </a>
         ], and intralesional injection of human chorionic gonadotropin [
         <a href="#rid75">
          75,76
         </a>
         ]. There is also emerging information regarding the salutary effects of the protease inhibitor
         <a class="drug drug_general" data-topicid="9685" href="/z/d/drug information/9685.html" rel="external">
          nelfinavir
         </a>
         as an anti-KS drug, and clinical trials are ongoing
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03077451&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPMf90pcqXZGZB01fUDiOLXgKxx2FfFc2Y7eHa%2FaMDMwDQ%3D%3D&amp;TOPIC_ID=8034" target="_blank">
          (NCT03077451)
         </a>
         .
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H97001260">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The development of combination ART and its application has led to a striking decrease in the incidence of KS and an improvement in the prognosis of patients with HIV-related KS, which frequently had been associated with early death. (See
         <a class="medical medical_review" href="/z/d/html/8033.html" rel="external">
          "AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis", section on 'Impact of antiretroviral therapy'
         </a>
         .)
        </p>
        <p>
         The prognosis of patients with HIV-related KS since the introduction of ART is illustrated by a consecutive series of 469 cases treated since 1998 at a single center [
         <a href="#rid77">
          77
         </a>
         ]. Of these, 303 presented with T0 disease (65 percent) and 166 had T1 involvement (35 percent). Those with T0 disease generally were treated with ART alone, unless there was a need for symptomatic treatment of localized lesions, while those with T1 disease were managed with chemotherapy plus ART. For those with T0 disease, the overall five-year survival was 92 percent and for those with T1 disease the five-year survival 83 percent. (See
         <a class="local">
          'Staging and evaluation'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H365157700">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/83959.html" rel="external">
          "Patient education: Kaposi sarcoma (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment approach
         </strong>
         – For HIV-positive patients who develop either limited or advanced Kaposi sarcoma (KS), we recommend that treatment include combined antiretroviral therapy (ART) (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). For some patients, ART maybe sufficient to induce regression of the KS. Others will require ART plus local or systemic chemotherapy. (See
         <a class="local">
          'Combined antiretroviral therapy'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">
          "Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Limited symptomatic disease
         </strong>
         – For patients who have limited disease causing symptoms or cosmetic disfigurement, we suggest local treatment rather than systemic chemotherapy in addition to ART (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Local symptomatic therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Intralesional chemotherapy
         </strong>
         – For patients with small lesions, we suggest intralesional chemotherapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Radiation therapy
         </strong>
         – For those with larger lesions that cannot be managed with intralesional chemotherapy, we suggest radiation therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications for chemotherapy plus combined ART
         </strong>
         – Indications for the addition of systemic chemotherapy to ART include extensive cutaneous disease; symptomatic visceral involvement; and cutaneous KS that is unresponsive to local therapy. (See
         <a class="local">
          'Systemic therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Chemotherapy is also indicated for patients with the immune reconstitution inflammatory syndrome (ie, progressive KS within weeks after initiation of ART). (See
         <a class="local">
          'Immune reconstitution inflammatory syndrome'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial therapy
         </strong>
         – For patients with AIDS-related KS who have an indication for systemic therapy, we suggest initial systemic chemotherapy with liposomal
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         rather than a combination of older agents or a taxane (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). However, liposomal doxorubicin may not be available in resource-limited settings, and in such cases,
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         is an acceptable alternative. (See
         <a class="local">
          'Liposomal doxorubicin (preferred)'
         </a>
         above and
         <a class="local">
          'Paclitaxel'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Subsequent therapy
         </strong>
         – The choice of subsequent therapy is dependent upon the pace of disease progression and symptoms.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with rapid progression on a liposomal anthracycline, we suggest chemotherapy with
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Paclitaxel'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with indolent progression on a liposomal anthracycline and ART, we suggest the use of
         <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">
          pomalidomide
         </a>
         as an alternative to chemotherapy, due to the potential for high response rates, favorable toxicity profile, and convenience of oral administration. (See
         <a class="local">
          'Indolent disease (pomalidomide)'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Dezube BJ. Clinical presentation and natural history of AIDS--related Kaposi's sarcoma. Hematol Oncol Clin North Am 1996; 10:1023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holland JC, Tross S. Psychosocial considerations in the therapy of epidemic Kaposi's sarcoma. Semin Oncol 1987; 14:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 1989; 7:1201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El Amari EB, Toutous-Trellu L, Gayet-Ageron A, et al. Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era. AIDS 2008; 22:1019.
          </a>
         </li>
         <li class="breakAll">
          Soft tissue sarcomas. In: AJCC Cancer Staging Manual, 8th ed, Amin MB (Ed), Springer, 2017.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dezube BJ, Pantanowitz L, Aboulafia DM. Management of AIDS-related Kaposi sarcoma: advances in target discovery and treatment. AIDS Read 2004; 14:236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bower M, Collins S, Cottrill C, et al. British HIV Association guidelines for HIV-associated malignancies 2008. HIV Med 2008; 9:336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krown SE. Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma. J Clin Oncol 2004; 22:399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gbabe OF, Okwundu CI, Dedicoat M, Freeman EE. Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults. Cochrane Database Syst Rev 2014; :CD003256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stebbing J, Sanitt A, Nelson M, et al. A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy. Lancet 2006; 367:1495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grabar S, Abraham B, Mahamat A, et al. Differential impact of combination antiretroviral therapy in preventing Kaposi's sarcoma with and without visceral involvement. J Clin Oncol 2006; 24:3408.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Franceschi S, Maso LD, Rickenbach M, et al. Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. Br J Cancer 2008; 99:800.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mocroft A, Kirk O, Clumeck N, et al. The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study. Cancer 2004; 100:2644.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gill J, Bourboulia D, Wilkinson J, et al. Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma--associated herpesvirus infection in patients with and without Kaposi sarcoma. J Acquir Immune Defic Syndr 2002; 31:384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gallafent JH, Buskin SE, De Turk PB, Aboulafia DM. Profile of patients with Kaposi's sarcoma in the era of highly active antiretroviral therapy. J Clin Oncol 2005; 23:1253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sgadari C, Barillari G, Toschi E, et al. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med 2002; 8:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinez V, Caumes E, Gambotti L, et al. Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy. Br J Cancer 2006; 94:1000.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krown SE, Lee JY, Dittmer DP, AIDS Malignancy Consortium. More on HIV-associated Kaposi's sarcoma. N Engl J Med 2008; 358:535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bower M, Nelson M, Young AM, et al. Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma. J Clin Oncol 2005; 23:5224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leidner RS, Aboulafia DM. Recrudescent Kaposi's sarcoma after initiation of HAART: a manifestation of immune reconstitution syndrome. AIDS Patient Care STDS 2005; 19:635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Letang E, Lewis JJ, Bower M, et al. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK. AIDS 2013; 27:1603.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Achenbach CJ, Harrington RD, Dhanireddy S, et al. Paradoxical immune reconstitution inflammatory syndrome in HIV-infected patients treated with combination antiretroviral therapy after AIDS-defining opportunistic infection. Clin Infect Dis 2012; 54:424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stover KR, Molitorisz S, Swiatlo E, Muzny CA. A fatal case of kaposi sarcoma due to immune reconstitution inflammatory syndrome. Am J Med Sci 2012; 343:421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Epstein JB. Treatment of oral Kaposi sarcoma with intralesional vinblastine. Cancer 1993; 71:1722.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCormick SU. Intralesional vinblastine injections for the treatment of oral Kaposi's sarcoma: report of 10 patients with 2-year follow-up. J Oral Maxillofac Surg 1996; 54:583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramírez-Amador V, Esquivel-Pedraza L, Lozada-Nur F, et al. Intralesional vinblastine vs. 3% sodium tetradecyl sulfate for the treatment of oral Kaposi's sarcoma. A double blind, randomized clinical trial. Oral Oncol 2002; 38:460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donato V, Guarnaccia R, Dognini J, et al. Radiation therapy in the treatment of HIV-related Kaposi's sarcoma. Anticancer Res 2013; 33:2153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olweny CL, Borok M, Gudza I, et al. Treatment of AIDS-associated Kaposi's sarcoma in Zimbabwe: results of a randomized quality of life focused clinical trial. Int J Cancer 2005; 113:632.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walmsley S, Northfelt DW, Melosky B, et al. Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group. J Acquir Immune Defic Syndr 1999; 22:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bodsworth NJ, Bloch M, Bower M, et al. Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel 0.1% in cutaneous AIDS-related Kaposi's sarcoma. Am J Clin Dermatol 2001; 2:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee FC, Mitsuyasu RT. Chemotherapy of AIDS--related Kaposi's sarcoma. Hematol Oncol Clin North Am 1996; 10:1051.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mosam A, Shaik F, Uldrick TS, et al. A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa. J Acquir Immune Defic Syndr 2012; 60:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hosseinipour MC, Kang M, Krown SE, et al. As-Needed Vs Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild-to-Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial. Clin Infect Dis 2018; 67:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin-Carbonero L, Barrios A, Saballs P, et al. Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma. AIDS 2004; 18:1737.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Northfelt DW, Dezube BJ, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 1998; 16:2445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stewart S, Jablonowski H, Goebel FD, et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol 1998; 16:683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cianfrocca M, Lee S, Von Roenn J, et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer 2010; 116:3969.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gill PS, Wernz J, Scadden DT, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 1996; 14:2353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young AM, Dhillon T, Bower M. Cardiotoxicity after liposomal anthracyclines. Lancet Oncol 2004; 5:654.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martín-Carbonero L, Palacios R, Valencia E, et al. Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin. Clin Infect Dis 2008; 47:410.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Welles L, Saville MW, Lietzau J, et al. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. J Clin Oncol 1998; 16:1112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gill PS, Tulpule A, Espina BM, et al. Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma. J Clin Oncol 1999; 17:1876.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tulpule A, Groopman J, Saville MW, et al. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma. Cancer 2002; 95:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee FC, Thornton K, Williams B. Low dose weekly paclitaxel is an effective first line treatment for patients with symptomatic AIDS-KS (abstract). Proc Am Soc Clin Oncol 2003; 22:825a.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lim ST, Tupule A, Espina BM, Levine AM. Weekly docetaxel is safe and effective in the treatment of advanced-stage acquired immunodeficiency syndrome-related Kaposi sarcoma. Cancer 2005; 103:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krown SE, Moser CB, MacPhail P, et al. Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial. Lancet 2020; 395:1195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz JD, Howard W, Scadden DT. Potential interaction of antiretroviral therapy with paclitaxel in patients with AIDS-related Kaposi's sarcoma. AIDS 1999; 13:283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nannan Panday VR, Hoetelmans RM, van Heeswijk RP, et al. Paclitaxel in the treatment of human immunodeficiency virus 1-associated Kaposi's sarcoma--drug-drug interactions with protease inhibitors and a nonnucleoside reverse transcriptase inhibitor: a case report study. Cancer Chemother Pharmacol 1999; 43:516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trattner A, Hodak E, David M, Sandbank M. The appearance of Kaposi sarcoma during corticosteroid therapy. Cancer 1993; 72:1779.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gill PS, Loureiro C, Bernstein-Singer M, et al. Clinical effect of glucocorticoids on Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1989; 110:937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nasti G, Errante D, Talamini R, et al. Vinorelbine is an effective and safe drug for AIDS-related Kaposi's sarcoma: results of a phase II study. J Clin Oncol 2000; 18:1550.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sprinz E, Caldas AP, Mans DR, et al. Fractionated doses of oral etoposide in the treatment of patients with aids-related kaposi sarcoma: a clinical and pharmacologic study to improve therapeutic index. Am J Clin Oncol 2001; 24:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evans SR, Krown SE, Testa MA, et al. Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi's sarcoma: an AIDS Clinical Trials Group clinical study. J Clin Oncol 2002; 20:3236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Busakhala NW, Waako PJ, Strother MR, et al. Randomized Phase IIA Trial of Gemcitabine Compared With Bleomycin Plus Vincristine for Treatment of Kaposi's Sarcoma in Patients on Combination Antiretroviral Therapy in Western Kenya. J Glob Oncol 2018; 4:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Busakhala N, Kigen G, Waako P, et al. Three year survival among patients with aids-related Kaposi sarcoma treated with chemotherapy and combination antiretroviral therapy at Moi teaching and referral hospital, Kenya. Infect Agent Cancer 2019; 14:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramaswami R, Polizzotto MN, Lurain K, et al. Safety, Activity, and Long-term Outcomes of Pomalidomide in the Treatment of Kaposi Sarcoma among Individuals with or without HIV Infection. Clin Cancer Res 2022; 28:840.
          </a>
         </li>
         <li class="breakAll">
          US Food and Drug Administration Label for Pomalidomide. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204026s023lbl.pdf (Accessed on May 19, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krown SE, Li P, Von Roenn JH, et al. Efficacy of low-dose interferon with antiretroviral therapy in Kaposi's sarcoma: a randomized phase II AIDS clinical trials group study. J Interferon Cytokine Res 2002; 22:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shepherd FA, Beaulieu R, Gelmon K, et al. Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: a Canadian HIV Clinical Trials Network study. J Clin Oncol 1998; 16:1736.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karp JE, Pluda JM, Yarchoan R. AIDS-related Kaposi's sarcoma. A template for the translation of molecular pathogenesis into targeted therapeutic approaches. Hematol Oncol Clin North Am 1996; 10:1031.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGarvey ME, Tulpule A, Cai J, et al. Emerging treatments for epidemic (AIDS-related) Kaposi's sarcoma. Curr Opin Oncol 1998; 10:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mocroft A, Youle M, Gazzard B, et al. Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. AIDS 1996; 10:1101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glesby MJ, Hoover DR, Weng S, et al. Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from the Multicenter AIDS Cohort Study. J Infect Dis 1996; 173:1477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin DF, Kuppermann BD, Wolitz RA, et al. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med 1999; 340:1063.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koon HB, Krown SE, Lee JY, et al. Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042. J Clin Oncol 2014; 32:402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005; 352:1317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krown SE, Roy D, Lee JY, et al. Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study. J Acquir Immune Defic Syndr 2012; 59:447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uldrick TS, Wyvill KM, Kumar P, et al. Phase II study of bevacizumab in patients with HIV-associated Kaposi's sarcoma receiving antiretroviral therapy. J Clin Oncol 2012; 30:1476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dezube BJ, Von Roenn JH, Holden-Wiltse J, et al. Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team. J Clin Oncol 1998; 16:1444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Little RF, Wyvill KM, Pluda JM, et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 2000; 18:2593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miles SA, Dezube BJ, Lee JY, et al. Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi's sarcoma. AIDS 2002; 16:421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dezube BJ, Krown SE, Lee JY, et al. Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study. J Clin Oncol 2006; 24:1389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Little RF, Pluda JM, Wyvill KM, et al. Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma. Blood 2006; 107:4650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Little RF, Aleman K, Kumar P, et al. Phase 2 study of pegylated liposomal doxorubicin in combination with interleukin-12 for AIDS-related Kaposi sarcoma. Blood 2007; 110:4165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gill PS, Lunardi-Ishkandar Y, Louie S, et al. The effects of preparations of human chorionic gonadotropin on AIDS-related Kaposi's sarcoma. N Engl J Med 1996; 335:1261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gill PS, McLaughlin T, Espina BM, et al. Phase I study of human chorionic gonadotropin given subcutaneously to patients with acquired immunodeficiency syndrome-related mucocutaneous Kaposi's sarcoma. J Natl Cancer Inst 1997; 89:1797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bower M, Dalla Pria A, Coyle C, et al. Prospective stage-stratified approach to AIDS-related Kaposi's sarcoma. J Clin Oncol 2014; 32:409.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 8034 Version 49.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8880194" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Clinical presentation and natural history of AIDS--related Kaposi's sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3603057" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Psychosocial considerations in the therapy of epidemic Kaposi's sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2671281" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18520345" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18520345" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15199854" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Management of AIDS-related Kaposi sarcoma: advances in target discovery and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18705759" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : British HIV Association guidelines for HIV-associated malignancies 2008.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14752065" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25221796" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16679162" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16849755" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Differential impact of combination antiretroviral therapy in preventing Kaposi's sarcoma with and without visceral involvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18665172" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15197808" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12447008" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma--associated herpesvirus infection in patients with and without Kaposi sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15718323" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Profile of patients with Kaposi's sarcoma in the era of highly active antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11875492" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16570046" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18234764" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : More on HIV-associated Kaposi's sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16051964" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16232048" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Recrudescent Kaposi's sarcoma after initiation of HAART: a manifestation of immune reconstitution syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23462220" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22095568" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Paradoxical immune reconstitution inflammatory syndrome in HIV-infected patients treated with combination antiretroviral therapy after AIDS-defining opportunistic infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22227511" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : A fatal case of kaposi sarcoma due to immune reconstitution inflammatory syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8448735" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Treatment of oral Kaposi sarcoma with intralesional vinblastine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8632242" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Intralesional vinblastine injections for the treatment of oral Kaposi's sarcoma: report of 10 patients with 2-year follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12110340" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Intralesional vinblastine vs. 3% sodium tetradecyl sulfate for the treatment of oral Kaposi's sarcoma. A double blind, randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23645769" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Radiation therapy in the treatment of HIV-related Kaposi's sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15472910" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Treatment of AIDS-associated Kaposi's sarcoma in Zimbabwe: results of a randomized quality of life focused clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10770343" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11705307" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel 0.1% in cutaneous AIDS-related Kaposi's sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8880196" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Chemotherapy of AIDS--related Kaposi's sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22395672" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29365083" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : As-Needed Vs Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild-to-Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15280789" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9667262" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9469358" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20564162" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8708728" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15522651" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Cardiotoxicity after liposomal anthracyclines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18582203" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9508198" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10561228" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12115328" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Low dose weekly paclitaxel is an effective first line treatment for patients with symptomatic AIDS-KS (abstract)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15578686" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Weekly docetaxel is safe and effective in the treatment of advanced-stage acquired immunodeficiency syndrome-related Kaposi sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32145827" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10202837" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Potential interaction of antiretroviral therapy with paclitaxel in patients with AIDS-related Kaposi's sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10321513" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Paclitaxel in the treatment of human immunodeficiency virus 1-associated Kaposi's sarcoma--drug-drug interactions with protease inhibitors and a nonnucleoside reverse transcriptase inhibitor: a case report study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8348508" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : The appearance of Kaposi sarcoma during corticosteroid therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2719427" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Clinical effect of glucocorticoids on Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10735904" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Vinorelbine is an effective and safe drug for AIDS-related Kaposi's sarcoma: results of a phase II study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11319295" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Fractionated doses of oral etoposide in the treatment of patients with aids-related kaposi sarcoma: a clinical and pharmacologic study to improve therapeutic index.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12149296" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi's sarcoma: an AIDS Clinical Trials Group clinical study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30241150" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Randomized Phase IIA Trial of Gemcitabine Compared With Bleomycin Plus Vincristine for Treatment of Kaposi's Sarcoma in Patients on Combination Antiretroviral Therapy in Western Kenya.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31516547" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Three year survival among patients with aids-related Kaposi sarcoma treated with chemotherapy and combination antiretroviral therapy at Moi teaching and referral hospital, Kenya.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34862247" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Safety, Activity, and Long-term Outcomes of Pomalidomide in the Treatment of Kaposi Sarcoma among Individuals with or without HIV Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34862247" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Safety, Activity, and Long-term Outcomes of Pomalidomide in the Treatment of Kaposi Sarcoma among Individuals with or without HIV Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12034036" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Efficacy of low-dose interferon with antiretroviral therapy in Kaposi's sarcoma: a randomized phase II AIDS clinical trials group study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9586886" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: a Canadian HIV Clinical Trials Network study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8880195" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : AIDS-related Kaposi's sarcoma. A template for the translation of molecular pathogenesis into targeted therapeutic approaches.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9800111" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Emerging treatments for epidemic (AIDS-related) Kaposi's sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8874626" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8648224" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from the Multicenter AIDS Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10194235" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24378417" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15800227" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Sirolimus for Kaposi's sarcoma in renal-transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22067664" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22430271" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Phase II study of bevacizumab in patients with HIV-associated Kaposi's sarcoma receiving antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9552050" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10893291" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Activity of thalidomide in AIDS-related Kaposi's sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11834954" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi's sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16549833" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16507779" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17846226" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Phase 2 study of pegylated liposomal doxorubicin in combination with interleukin-12 for AIDS-related Kaposi sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8857005" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : The effects of preparations of human chorionic gonadotropin on AIDS-related Kaposi's sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9392621" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Phase I study of human chorionic gonadotropin given subcutaneously to patients with acquired immunodeficiency syndrome-related mucocutaneous Kaposi's sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24378415" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Prospective stage-stratified approach to AIDS-related Kaposi's sarcoma.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
